BioLife Solutions, Inc. (BLFS)

Environment story

BioLife Solutions operates in the cell and gene therapy support space with minimal direct manufacturing footprint relative to upstream supply chain. Scope 1 and Scope 2 emissions data are not disclosed in the 10-K; this omission triggers a 15-point deduction from the Environmental pillar. No net-zero target year is disclosed (additional 15-point deduction). The company manufactures biopreservation media and thaw devices at facilities in Bothell, Washington and Indianapolis, Indiana, both subject to cGMP standards but with no explicit renewable energy or carbon-mitigation disclosures. No material environmental controversies, toxic-waste litigation, or water-consumption issues are documented in the filing. The company has not disclosed investments in physical decarbonization infrastructure. The lack of comprehensive emissions reporting and climate commitments significantly constrains the environmental score, though the absence of negative controversies prevents further penalization.

Social story

BioLife Solutions employs 155 full-time team members as of December 31, 2025, with no documented union-suppression activities, major strikes, or labor litigation within the past 24 months. CEO-to-median-worker pay ratio is not disclosed; in the absence of data suggesting a ratio exceeding 200:1, no deduction is applied. Leadership diversity (executive and board composition) percentages are not disclosed in the 10-K; absence of disclosure prevents confirmation of diversity below 30%, though no explicit diversity initiatives or programs are mentioned. The company emphasizes competitive compensation at or above market rates, pay-for-performance incentives, and hybrid work arrangements. Supply-chain human-rights audits are not documented. The social audit reflects adequate labor practices and benefits offerings, with the primary limitation being incomplete diversity transparency and lack of formalized supply-chain ethics oversight.

Governance story

BioLife Solutions' governance structure reflects standard Delaware incorporation with several protective provisions that limit shareholder activism. The 10-K discloses that a significant percentage of outstanding common stock is held by one stockholder with substantial influence over corporate actions (triggering awareness of concentrated ownership). The company has not disclosed board independence percentage; in the absence of explicit data, no deduction for independence below 75% is applied, though the concentration risk is noted. No dual-class share structure is explicitly disclosed, so the 20-point deduction for unequal voting rights is not applied. Lobbying expenditures are not disclosed; the company operates in the life sciences / bioproduction sector with no evident climate-deregulation or consumer-protection-rollback lobbying documented in the filing. No material antitrust, consumer-safety, or financial-fraud proceedings are disclosed. The company has experienced historical material weaknesses in internal control over financial reporting, though management concluded controls were operating effectively as of December 31, 2025. The governance score reflects adequate baseline controls with limitations in transparency regarding board composition and shareholder structure.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of BioLife Solutions, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open BioLife Solutions, Inc. in the app for interactive charts and portfolio building.

More in Healthcare